IPOXINS ARE conjugated tetraene-containing eico-L sanoids that possess potent biologic actions.'" Lipoxins are generated in microgram quantities by single-cell types such as activated macrophages of rainbow trout4 or in nanogram levels by transcellular biosynthetic routes documented during cell-cell interaction^,^ in particular, those observed during human neutrophil-platelet and eosinophil transcellular biosynthesis of eico~anoids.~,~,~ Their formation in human cell types can be triggered by either initial oxygenation of arachidonic acid by 5-lipoxygenase followed by interactions with 1 2-lipoxygenase5 or by 1 5-lipoxygenation and interaction with 5-lipoxygenase and subsequent reaction^.^ One member of this series, lipoxin A, (LXA,), has been documented in vivo in bronchoalveolar lavage fluids from patients with pulmonary diseases,' and is generated by intracoronary components in patients undergoing balloon angioplasty* and after activation of human bone marrow ex vivo.g LXA, is active with some cell types in the nanomolar range,'-" suggesting that it can play important regulatory roles. It both stimulates vasodilation and can counter the proinflammatory actions of leukotriene (LT) D," and LTB4I3 observed in animal in vivo models. LXA, has also recently been shown to modulate LTC,-induced airway obstruction after inhalation by asthmatic patient^.'^ Human neutrophils (polymorphonuclear leukocytes [PMN] ) exposed (15 minutes, 37°C) to LXA, (IC5o = lo-* mol/L) in vitro are less responsive when challenged with either the chemotactic peptide (FMLP) or LTB, .lo,'' In addition, LXA, ( mol/L) stimulates colony formation in human marrow cells treated with suboptimal concentrations of granulocyte-macrophage colony-stimulating factor (GM-CSF).9 Together, results of these studies suggest that lipox- ins may represent regulatory molecules in cellular events ranging from those involved with human myelopoiesis to pulmonary inflammation.
Although it is now clear that lipoxins carry potent biologic activities, their mechanism(s) of action remain to be elucidated. Human PMN exposed to LXA, rapidly remodel (within 5 to 15 seconds) their membrane lipids in a pertussis toxin-sensitive fa~hion.'~ Recently, we have found that PMN possess specific recognition sites for LXA, (kd = 0.5 nmol/L) that may mediate its actions.I6 Here, we present the first evidence indicating that differentiation of the human acute promyelocytic leukemic cell line (HL-60) results in the appearance of specific [ 1 I , 1 2-3H]LXA, binding sites that confer a functional response, namely lipid remodeling in both HL-60 cells and PMN. 
MATERIALS AND METHODS

Materials
HL-60 cells were purchased from the American Type Culture Collection (ATCC, Rockville, MD). RPMI medium and cell culture reagents were from GIBCO (Grand Island, NY [PB) . Human PMN were obtained by the modified Boyum method2' from fresh heparinized blood after venipuncture of healthy normal volunteers. Suspensions in PBS were monitored for cell number and viability by their ability to exclude trypan blue both exceeding 98%. RBCs were obtained from I O mL of heparinized blood after three centrifugations in PBS (2,500 rpm, I O minutes at 2 1 "C). Blood drawn in acidic citrate dextrose (9: I , vol/vol) was used to isolate platelets as previously described. ' 'H-LXA, and 'H-LTB, binding was performed essentially the same as by Fiore et Results represent the mean f SEM from three separate experiments.
After 10 minutes, wells were washed twice with PBS and cell-associated label was recovered by adding glacial acetic acid (0.5 mL). Results obtained from these assays were submitted for further analysis using the Ligand program (Elsevier-Biosoft, Cambridge, UK).
Phospholipase D (PLD) activity. Human PMN and HL60 cells (50 X 1 O6 cells/mL) prepared as above were incubated with 'H-myristic acid or 3H-palmitic acid (8 pCi/5O X IO6 cells) for 40 to 60 min at 37°C in PBS. Cell uptake ranged between 60% and 80% of added label, 7.1% F 4.2% (n = 10; mean +SD) and 32.6% + 10.3% (n = 6; mean &SD) into total PL classes of PMN and HL-60 cells, respectively. Incubations were performed at 37°C (10 X lo6 cells/l mL PBS). Agonists were added in 50 pL PBS or with 1:lO (vol/vol) Et0H:PBS for phosphatidylethanol (PEt) formation as described by Billah et al?' At indicated times, incubations were stopped by adding 3.5 mL of ice-cold CHCl,/MeOH (2/5, vol/vol) containing 1 -'4C-arachidonic acid (5,000 cpm) used here as internal standard to quantitate extraction recoveries. Samples were extracted using a modified Bligh and Dyer extraction as described by Nigam et al." Organic phases, concentrated in 50 p L of CHCI,/MeOH (8/2, vol/ vol), were spotted onto linear K6D TLC plates (Fisher) developed with the organic phase of ethyl acetate/isooctane/acetic acid/water (1 10/50/20/ 100, vol/vol/vol/vol) for 50 minutes.22 In this system, phosphatidic acid (PA) gave an Rf = 0.1 + 0.04 and PEt (Rf = 0.56 f 0.04; n = 38 +SD) that were clearly separated from other PLs (that remained at the origin) or neutral lipids (Rf = 0.75 to 0.90). Lipids were visualized with iodine vapor and identified by coelution with authentic standards that were also spotted and chromatographed in each TLC plate. Regions corresponding to PA, PEt, and internal standards were scraped and quantified by liquid scintillation counting. In addition to 'H-myristate or 'H-palmitate labeling, both [I-'4C]arachidonate (0.25 pCi/30 X lo6 PMN) and 32PyATP (20 pCi/50 X lo6 PMN) labeled cells were used to monitor LXA4-stimulated formation of PA and PEt generation. In these experiments, PA was resolved using ethyl acetate/isooctane/acetic acid (45/ I5/ 10, vol/vol/vol) as solvent system2' and gave an Rf Tables 4 and 5) were calculated by subtracting the disintegrations per minute obtained in the presence of agonist(s) alone from those measured in the presence of agonist(s) and 0.5% EtOH.
Impact of IAP and staurosporine on LXA,-induced PLD activ-
ity. PLD activity assays, performed as described (vide supra), were preceded by cell exposure to either IAP or staurosporine. IAP treatment of PMN was performed as previously described," and HL-60 cells were incubated in the presence or absence of IAP (300 ng/mL) for 2 hours at 37°C.24 Aliquots (IO' cells/0. mL buffer. Next, incubated cells were exposed to either 100 pL of vehicle (PBS, EtOH 0.04%) or LXA, (lo-' mol/L and IO-' mol/L), in the presence or absence of0.5% EtOH. Staurosporine (100 nmol/ L) was added to cell suspensions for 5 minutes at 37°C before addition of LXA,.
RESULTS
After preparation of synthetic [ 1 I ,12-'H]LXA4, we characterized its specific binding to promyelocytic cells (HL-60) and performed direct comparisons with specific binding of [ 14,l S3H]LTB,. When routine phenotypic markers were monitored (Table I) , untreated HL-60 cells displayed a low level of specific binding for both 'H-LXA, and 'H-LTB, ligands (Fig I) . Differentiation induced by exposure to either DMSO (1.12%) or RA (1 pmol/L) for 5 days ( Table 1) was accompanied with a threefold to fivefold increase in specific binding for both radioligands (Figs 1 and 2 ). PMAtreated cells (20 nmol/L, 48 hours) displaying characteristics of macrophagic-like phenotype, ie, nitro blue tetrazolium-negative cells that adhere to p l a s t i~'~~~~ (see Table I ), also led to the appearance of specific binding with both 3H-LXA, and 3H-LTB, (Figs I and 2 ). Equilibrium binding with 3H-LXA, at 4°C was reached at 10 minutes that remained virtually unchanged for the next 20 minutes (data not shown).
To assess whether induction of specific binding for both 3H-ligands required de novo synthesis, actinomycin D (2 pg/mL) was added with PMA incubations. Actinomycin D blocked the PMA-induced increment in specific binding (Fig 1) for both labeled eicosanoids, suggesting inhibition of de novo protein biosynthesis also blocked appearance of specific binding sites. The impact of protease and glycosidase treatments was assessed with both differentiated HL-60 cells and human PMN for 'H-LXA,-specific binding. Protease treatment reduced specific binding and provided additional evidence in support of a protein component of LXA, specific binding sites (Table 2) .
Results from isotherm binding assays (4"C, 10 minutes) with differentiated HL-60 cells and [ 1 I , 1 2-3H]LXA4 (0.1 to 30 nmol/L) showed that [ 1 I , 1 2-3H]LXA,-specific binding sites gave a kd = 0.6 f 0.3 nmol/L (Fig 3) . A nonlinear portion of the Scatchard plot was observed for concentrations (0.2 nmol/L. These results were similar to those ob- were assessed as potential competing ligands. Neither LXB,, LTB,, nor trihydroxyheptanoic acid (methyl ester) (300 nmol/L) were able to displace 'H-LXA,-specific binding with differentiated HL-60 cells while LTC, caused -30% decrease of specific binding when added in 3-log molar excess (data not shown). Also, the finding that LXA, (300 nmol/L) was unable to compete 'H-LTB, (0.3 nmol/L) binding to differentiated HL-60 cells suggests that LXA, and LTB, interact with separate classes of specific binding sites. Leukotriene receptor antagonists SKF 104353 and ONO-4057 did not displace 'H-LXA, binding with differentiated HL-60 cells, but SKF 104353 and LTD, were effective in competing the specific 'H-LXA, binding with HU-VEC (Table 3 and Fig 4) . HUVEC displayed a kd of 1 1 .O ? 2.6 nmol/L and a B , of 2.5 X IO-'' mol/L for 'H-LXA,, and virtually identical values were calculated for LTD, competition. In the case of 3H-LTB,, HUVEC did not specifically bind LTB,, but nonspecific cell association was evident with this 'H-ligand (n = 3; not shown). Specific association of 'H-LXA, was not evident among several other cell types surveyed (Table 3) . Here, neither washed platelets, RBCs, the B-cell (Raji), nor T-cell (Jurkat) cultured cell lines display specific binding for 'H-LXA,. Taken together, these results indicate that LXA, interacts with unique binding sites in differentiated HL-60 cells that are not sensitive to either leukotriene receptor antagonists (SKF 104353 or ONO-4057). In HUVEC, 'H-LXA,-specific binding was sensitive to both LTD, and SKF 104353 but not ONO-4057 (Fig 4) , suggesting that 'H-LXA,-specific binding in this cell type may reflect its interaction with putative LTD, receptors.
LXA, rapidly stimulates phosphatidic acid formation in human neutrophil^.'^ To determine if 'H-LXA, binding confers PLD activation, PEt and PA were monitored in both PMN and HL-60 cells. Results in Fig 5 indicate that LXA, stimulates PLD activity in these cell types with similar temporal responses. PMN exposed to LXA, (lo-'' mol/ L) rapidly generated the ethanol-trapping product PEt (see Methods) within 60 seconds that decreased to baseline levels by 5 minutes. In the absence of added EtOH, PEt was not formed at statistically significant levels. A biphasic concentration dependence was obtained for PEt formation in both PMN (Fig 5A insert) and differentiated HL-60 cells (Fig 5B  insert) . An apparent maximal response was noted with the concentration range of -to lo-'' mol/L LXA,, and a second peak of activity was observed at mol/L LXA,. Below lo-* mol/L, both the chemotactic peptide FMLP and LXA, gave results of similar magnitude with FMLP appearing to be slightly more potent with PMN from some donors (not shown). To evaluate the potential contribution ofother biosynthetic pathways, LXA,-induced PA formation was also examined in both 32PyATP and [ 1 -14C]arachidonatelabeled PMN. 32P-labeled PA was evident in statistically significant levels only after 30 minutes of exposure to LXA, ( IOT7 mol/L). Similar results were obtained with 14C-labeled PA formation derived from 14C-arachidonate-labeled precursors. These findings indicated that LXA, can also stimulate other routes of PA formation in PMN, but only after 30 minutes of exposure.
Only differentiated HL-60 cells (expressing specific binding sites for 'H-LXA,) incubated with LXA, rapidly generated PEt that was evident within 30 seconds. Undifferentiated HL-60 cells incubated with LXA, ( mol/L) did not rapidly generate PEt. The concentration dependence with these cells also gave a biphasic response with LXA, and gave an apparent maximum at mol/L. To investigate possible signal transduction events involved in LXA,-mediated PLD activation, we next exposed PMN and HL-60 cells to either IAP or staurosporine. Results shown in Tables  4 and 5 indicate that the LXA,-mediated PLD activity evoked within the lower concentration range (lo-' to lo-'' mol/L) was sensitive to IAP treatment in both cell types and, similarly, the PLD activity stimulated at higher con- centrations of LXA, (lo-' mol/L) was inhibited by staurosporine. Thus, in both cellular systems at concentrations below 1 O-* mol/L, LXA, rapidly interacts with specific binding sites that trigger PLD activity and hence confers a functional response, while within submicromolar concentrations of LXA,, it may stimulate additional processes that can also lead to activation of PLD.
DISCUSSION
LXA, elicits stereospecific responses in both mammalian and nonmammalian cell types and tissues (as reviewed in Samuelsson et a12 and Serhan3). These include potential immunoregulatory actions such as those displayed with human natural killer (NK) cells3 as well as recently described actions in stimulating myelopoiesis.' At pharmacologic levels, LXA, can also counteract the actions of LTs by blocking both contractile actions of LTs in humans', and inhibiting LTB,-induced inflammation in the hamster cheek pouch. 13 The mechanisms underlying LXA, actions are currently being investigated. Along these lines, we recently prepared synthetic tritiated LXA, and documented the presence of highaffinity recognition sites for 3H-LXA4 with human neutrophils.I6 Here, we have extended these studies and present evidence for the appearance of specific 3H-LXA4 recognition sites on differentiation of HL-60 cells in vitro (Figs 1 and 2 ) that confers a functional response in both HL-60 cells and neutrophils derived from PB, namely the activation of a key enzyme involved in PL remodeling (Fig   The binding of [ 1 I, 1 2-' H]LXA4 to differentiated HL-60 cells was time-dependent, saturable, reversible, and specific for the homoligand LXA, (Figs 1 and 2 ). In the absence of differentiating agents, low-specific binding that was statistically not significant was noted for both 3H-LXA4 or 3H-LTB, (Table I) . Recent results of Ha~-ada*~ indicate that DMSO-differentiated HL-60 cells display LTB, binding sites that trigger mobilization of intracellular Ca2+ on addition of agonist. The present results with 3H-LTB4 binding (Fig 1) are consistent with these" and show that the appearance of both specific LXA, binding sites and LTB, binding sites are obtained with the routinely used differentiating agents, ie, DMSO, RA, and PMA (Table I ). The induction of both ligand binding sites appears to be independent ofthe type of differentiating agent used (Fig 2) . As recently found with PMN, where the number of LTB, sites is greater than LXA, recognition sites,16 differentiated HL-60 cells displayed two to three times more sites for LTB, than LXA, (Fig I and Table 1 ). Neither LTB, nor LXA, cross-reacted with their respective recognition sites in differentiated HL-60 cells. Both DMSO and RA are reported to induce differentiation of HL-60 toward neutrophil-like and PMA induces macrophage-like phenotype^.'^^^^ The characteristic of these phenotypes was monitored in the present expenments and both NBT positive and adherent HL-60 cells gave specific binding with 3H-LTB, and 3H-LXA, ( Table 1) .
The 3H-eicosanoids were displaced by their respective unlabeled homoligand (Fig 2) . Nonspecific binding at 4°C (ie, the amount not displaced by the homoligand when added at 3-log order excess) was ~4 0 % to 50% for both LTB, and LXA,. These values for nonspecific binding are consistent with those reported earlier for both ligand^'^,^' and may not only reflect their lipid nature but can be related to their carrier-mediated transport systems in these cells (Simchowitz L, Fiore S, Serhan CN, manuscript in preparation). Subcellular fractionation of PMN showed that -23% of LXA,-specific binding is associated with fractions enriched in nuclei; 34% with those of granules and 42% with those enriched with plasma membrane. Specific binding of [ 1 1,1 2-3H]LXA, was also selectively regulated by guanosine stable analogs. 16 Here, treatment of both PMN and differentiated HL-60 cells with the proteases papain, pronase, chymotrypsin, and proteinase K significantly reduced specific binding of [ Table 2 ), suggesting that the recognition sites may contain protein components critical for binding.
5).
For mol/L). Parallel incubations were exposed for 5 minutes to staurosporine (100 nmol/L) before agonist additions. Next, incubations were stopped, extracted, and the organic phases were spotted and resolved by thin-layer chromatography. Results are the mean f SD from an experiment performed in triplicate and are representative of three separate experiments.
* Time 0 points were taken immediately after cell resuspension in buffer by adding vehicle containing buffer to incubations exposed to IAP or staurosporine. 
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Isolated PMN were labeled and incubated for 90 minutes at 37°C in the presence or absence of IAP (2 pg/mL) and DNAse type I as previously de~cribed.'~ Next, PMN (lo7 cells/mL) were exposed for 30 seconds to vehicle containing either EtOH alone (0.04% vehicle, 0.5% final EtOH for trapping), or with LXA, (1 0-7 mol/L or 5 x 1 0-" mol/L). Parallel incubations were exposed for 5 minutes to staurosporine (1 00 nmol/L) before agonist additions. Incubations were stopped, extracted, and the organic phases were spotted and resolved by TLC. Results are the average of duplicate determinations from one representative experiment of three separate ones. * %PLD, , .
was calculated using the highest amount of 'H-PEt obtained with LXA, as stimulus. cell type is at present unknown but may serve to enhance the actions of LXA, when generated in low levels such as those that may be encountered in, for example, bone marrow. Although positive cooperative binding of eicosanoids has not been previously appreciated, recent results from computer modeling of leukotriene binding data suggest that LTC, triggers allosteric interactions between two different binding sites present in the same receptor molecule.'' These findings are of particular interest in view of the present data for LXA, (Fig 3) and indicate that additional experiments are required to evaluate its validity and potential functional significance. Of the cell types surveyed at present, [ 1 1,l 2-,H]LXA, was found to be associated to some degree with human platelets, RBCs, or the T-and B-cell lines. However, specific binding (displacement/competition with excess homoligand) was evident only with PMN, differentiated HL-60, and human endothelial cells (Table 3) . With retinoic acid-differentiated HL-60 cells, neither LXB,, LTB,, nor the LT-receptor antagonists (SKF 104353 or ONO-4057) were effective in displacing LXA,, and LTC, decreased specific binding of (Fig 4B) . Recently, we have found that with HUVEC, LTD, stimulates the release of von Willebrand's factor (vWF) that was inhibited by SKF 104353 implicating the presence of functional LTD, receptors.29 LXA, antagonizes the actions of LTD, in vivo and appears to interact with LTD, receptors in rat mesangial cells because both SKF 104353 and LXA, block inositol triphosphate (InsP,) formation." HUVEC specifically bind LXA, at a kd of 1 1.0 f 2.6 nmol/L. LXA,-specific binding was For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From inhibited by LTD, and SKF 104353 in HUVEC but not with HL-60 cells (Fig 4) . Thus, it appears that the recognition sites for LXA, are different in both of these cell types. With HUVEC, [ 1 I , 12-3H]LXA, probably interacts with an LTD, receptor class, while in differentiated HL-60 cells and PMN it binds to unique recognition sites (Fig 4) .
The appearance of recognition sites for LXA, that serve as functional receptors in HL-60 cells and PMN is supported by the finding that specific binding of LXA, confers activation of PLD (Fig 5, Tables 4 and 5) . PLD activation is important in lipid remodeling and its activity is regulated by G protein^.'^ In the presence of EtOH, both PMN and differentiated HL-60 cells rapidly (<60 seconds) generated PEt (a marker of PLD activity22) on exposure to LXA4. Because undifferentiated HL-60 cells neither generate significant amounts of PEt (Fig 5B) nor specifically bind appreciable amounts of [ 1 l,12-3H]LXA, ( Table 1 and Fig 1) and PLD activity is present in both differentiated and undifferentiated HL-60 cell^,^^^"^^' specific binding of LXA, confers activation of PLD. In this regard, LXA, was approximately a log order o f magnitude more potent with PMN (IC,' x IO-'' mol/L) than with differentiated HL-60 cells (IC5' x mol/L). Yet both cell types displayed a biphasic response when exposed to LXA,, and at concentrations greater than lo-' mol/L it may activate PLD by mechanisms that are separate from "classical cell surface receptorligand" interactions. In this regard, cells exposed to either IAP (an inhibitor of GI-and Go-protein-mediated responses), or staurosporine (a potent protein kinase C [PKC] inhibitor) showed differential PLD responses to LXA, in the subnanomolar range ( to IO-" mol/L) as well as in the submicromolar range ( mol/L). Staurosporine, in addition to its PKC inhibitor activity, has recently been shown to activate PLD in rabbit neutrophils via direct interaction with several G-protein subclasses.32 Our results (Table 4) are in agreement with this observation showing that maximal PLD activation is rapidly obtained after human cells are exposed to staurosporine (100 nmol/L, 5 minutes at 37°C). Staurosporine-induced PLD activity is reduced on subsequent exposure of cells to LXA, ( IO-' mol/L) and only partly affected by addition of LXA, in the to IO-" mol/L range. Similar responses were observed with PMN (Table 5) . Thus, these results suggest that some of the previously reported LXA, inhibitory effects on cellular responses elicited via receptor-mediated ~t i m u l i '~'~.~' could arise from a complex series of interactions involving both G-protein and PKC-mediated signal transduction events. For example, at high concentrations mol/L), LXA, may bypass receptor-ligand interactions crossing plasma membranes via a specific camer-mediated intracellular transport (Simchowitz L, Fiore S, Serhan CN, manuscript in preparation) to activate key target enzymes such as PKC. Indeed, LXA, as its native-free acid (but not its methyl ester form) can stimulate isolated isozymes of PKC in vitro (as reviewed in Samuelsson et a12 and Serhan'). LXA, methyl ester is able to compete for 'H-LXA, binding and induces release of arachidonic acid at subnanomolar concentrations ( IO-'' mol/L) with PMN, while only the native-free acid is able to cause a second peak of activity that registers in the submicromolar concentrations.'6 These findings are in agreement with the present data indicating that LXA, activates PLD in a biphasic concentration-dependent fashion via two components: one consistent with the presence of a surface receptor (lo-'' mol/L peak activity), and a second phase consistent with its ability to stimulate intracellular targets such as PKC ( mol/L peak activity). Recently, LXA, and an analog (trihydroxyheptanoic acid and its methyl ester) were found to inhibit PMN activation at IO-'' mol/L." In the present studies, trihydroxyheptanoate did not compete for [ 1 I , 12-'H]LXA,-specific binding at 4°C. Thus, it is possible the subclasses ofdistinct LX binding sites may exist or the trihydroxyheptanoate may elicit its inhibitory actions through a PKC-mediated event. Hence, LXA, appears to display multiple modes of action that are concentration-dependent.
Their complete characterization awaits further experiments.
In summary, the present results indicate that specific LXA, recognition sites are induced in HL-60 cells that confer lipid remodeling events. They should also facilitate further characterization of LXA, and other eicosanoid receptors.
